John B. Moriarty Sells 167 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP John B. Moriarty sold 167 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $126.84, for a total transaction of $21,182.28. Following the completion of the transaction, the executive vice president now directly owns 46,476 shares in the company, valued at $5,895,015.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 126.51 on Friday. The stock’s 50 day moving average is $131.00 and its 200 day moving average is $127.05. The company has a market capitalization of $28.33 billion, a P/E ratio of 77.14 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52-week low of $109.12 and a 52-week high of $162.00.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

WARNING: “John B. Moriarty Sells 167 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock” was reported by sleekmoney and is the property of of sleekmoney. If you are accessing this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright law. The original version of this piece can be read at http://sleekmoney.com/john-b-moriarty-sells-167-shares-of-alexion-pharmaceuticals-inc-alxn-stock/1655516.html.

ALXN has been the topic of a number of recent analyst reports. Vetr cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $107.00 price objective on the stock. in a research note on Tuesday, October 18th. FBR & Co raised shares of Alexion Pharmaceuticals from an “underperform” rating to a “market perform” rating and set a $130.00 price objective on the stock in a research note on Friday, October 28th. Goldman Sachs Group, Inc. (The) raised shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $158.00 price objective on the stock in a research note on Friday, October 28th. Wedbush lifted their price objective on shares of Alexion Pharmaceuticals from $132.00 to $135.00 and gave the company a “neutral” rating in a research note on Friday, October 28th. Finally, Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 2nd. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average price target of $170.70.

Several institutional investors have recently added to or reduced their stakes in ALXN. Global X Management Co. LLC boosted its stake in shares of Alexion Pharmaceuticals by 1,416.4% in the third quarter. Global X Management Co. LLC now owns 925 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 864 shares during the last quarter. Cornerstone Advisors Inc. boosted its stake in shares of Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 310 shares during the last quarter. Acrospire Investment Management LLC boosted its stake in shares of Alexion Pharmaceuticals by 50.0% in the third quarter. Acrospire Investment Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 400 shares during the last quarter. Bellwether Investment Group LLC purchased a new stake in shares of Alexion Pharmaceuticals during the second quarter valued at $172,000. Finally, NEXT Financial Group Inc boosted its stake in shares of Alexion Pharmaceuticals by 37.7% in the third quarter. NEXT Financial Group Inc now owns 1,523 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 417 shares during the last quarter. 96.60% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/john-b-moriarty-sells-167-shares-of-alexion-pharmaceuticals-inc-alxn-stock/1655516.html

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *